Compare First Solar, Inc. (FSLR) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
First Solar, Inc. vs Tango Therapeutics Inc. — how do they compare? First Solar, Inc. trades at $177.76 (market cap $20.05B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: First Solar, Inc. is far larger — about 5.3× Tango Therapeutics Inc.'s market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, First Solar, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold First Solar, Inc. for 76 Days and Tango Therapeutics Inc. for 0 Days on average.
| FSLR | TNGX | |
|---|---|---|
Market Cap | $20.05B | $3.75B |
Volume | 2,420,017 | 9,619,106 |
Sector | Energy | Health |
52-Week High | $318.30 | $32.90 |
52-Week Low | $172.11 | $7.50 |
Typical Hold Time | 76 Days | 0 Days |
Enterprise Value | $18.52B | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
First Solar (FSLR) trades at $179.08, down 0.36% with bearish technical signals despite strong fundamentals. The stock shows robust revenue growth from $2.6B in 2022 to $5.2B in 2025, with net income margins exceeding 29%. Recent earnings beat expectations in Q1 and Q2 2026, though Q4 2025 missed estimates. Analyst consensus remains positive with a $268.82 price target, while technical indicators show resistance near $181 with oversold RSI conditions.
FSLR presents a value opportunity with attractive valuation multiples (P/E 11.5, P/S 3.73) and strong profitability (ROE 18.51%). Risks include sector-wide pressure from high borrowing costs, patent litigation uncertainties, and recent insider selling. The stock's 35% decline from peaks creates potential upside if solar sector sentiment improves.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About First Solar, Inc.
First Solar designs and manufactures solar photovoltaic panels, modules, and systems for use in utility-scale development projects. The company's solar modules use cadmium telluride to convert sunlight into electricity. This is commonly called thin-film technology. First Solar is the world's largest thin-film solar module manufacturer. It has production lines in Vietnam, Malaysia, the United States, and a new factory under construction in India.
Read more on FSLR →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
